Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

22.08B

Market cap22.08B

Price-Earnings ratio

8.33

Price-Earnings ratio8.33

Dividend yield

—

Dividend yield—

Average volume

3.11M

Average volume3.11M

High today

$180.61

High today$180.61

Low today

$163.01

Low today$163.01

Open price

$172.36

Open price$172.36

Volume

7.06M

Volume7.06M

52 Week high

$479.79

52 Week high$479.79

52 Week low

$163.01

52 Week low$163.01

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $165.88. The company's market cap stands at 22.08B, with a P/E ratio of 8.33.

On 2026-10-31, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $163.01 and a high of $180.61. Shares are currently priced at $165.88, which is +1.8% above the low and -8.2% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 7.06M, against a daily average of 3.11M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $163.01.

ALNY News

Simply Wall St 12h

Alnylam Pharmaceuticals Stock Falls As Q3 Earnings Lean On Tax Gain - Simply Wall St

...

Seeking Alpha 22h

Alnylam downgraded at Bernstein on TRITON-CM trial design

Bernstein on Friday downgraded Alnylam Pharmaceuticals (ALNY) to Market Perform from Outperform, citing concerns over the design of its TRITON-CM Phase 3 trial...

Zacks 23h

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Alnylam Pharmaceuticals (ALNY Quick QuoteALNY - Free Report) reported third-quarter 2026 adjusted earnings of $16.26 per share, beating the Zacks Consensu...

Analyst ratings

67%

of 33 ratings

Buy

66.7%

Hold

33.3%

Sell

More ALNY News

Simply Wall St 1d

Alnylam Pharmaceuticals Could Be 53% Undervalued As Earnings And Trial Data Impress

Advertisement Why Alnylam Pharmaceuticals Stock Is Back in Focus Alnylam Pharmaceuticals (ALNY) just combined a big earnings surprise with fresh clinical data...

Zacks 3d

Alnylam Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Analysts on Wall Street project that Alnylam Pharmaceuticals (ALNY Quick QuoteALNY - Free Report) will announce quarterly earnings of $2.19 per share in i...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.